Skip to content

Released Mar 23, 2021, after the close

10-K filed Mar 23, 2021, 82 days after period end · 0001390478-21-000007

Q4 2020 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$1.90Mderivedno prior Q4 2019 on fileno prior Q3 2020 on file
Net Income-$3.72MderivedN/M vs Q4 2019N/M vs Q3 2020
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$4,159,000—
Operating Cash Flowderived$3,424,000N/M
Margins · derived
Operating margin-218.9%
Net margin-195.6%

What the release said

The release

Same quarter

MetricQ4 2020derived from reported figuresQ4 2019derived from reported figuresQ4 2018derived from reported figuresQ4 2017derived from reported figures
Revenue$1.90M———
Net Income-$3.72M-$7.42M-$13.32M-$8.79M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR